

19 January 2017

## Final Trading Day for ANPO Listed Options

ASX has requested the Company to correct its previous announcement in relation to the expiration of the ANPO listed options exercisable at \$0.27 per option on or before 31 January 2017.

Due to the Australia Day Public Holiday being a Non-Business Day, Quotation of these expiring ANPO options will end at Close of Trading on Tuesday 24<sup>th</sup> January 2017, not Wednesday 25<sup>th</sup> of January 2017 as previously advised.

**Contact Information:** Website: [www.antisense.com.au](http://www.antisense.com.au)  
Managing Director: Mark Diamond +61 (0)3 9827 8999

**Antisense Therapeutics Limited** (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS) , ATL1103 drug designed to block GHR production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.